Abstract
In the brain after infarction or trauma, the tissue becomes pannecrotic and forms a cavity. In such situation, a scaffold is necessary to produce new tissue. In this study, we implanted a new porous gelatin-siloxane hybrid derived from gelatin and 3-(glycidoxypropyl) trimethoxysilane (gelatin-GPTMS) scaffolds into a brain defect, and investigated whether it makes a new brain tissue. In addition, vascular endothelial growth factor (VEGF) was added on gelatin- GPTMS scaffolds and its effect on tissue regeneration was examined. At 30 days after the implantation, the marginal territory of the scaffolds became occupied by newly formed tissue. Immunohistochemical analysis revealed that the new tissue was constituted by endothelial, astroglial and microglial cells, some of which were labeled for bromodeoxyuridine (BrdU). Addition of VEGF promoted numbers of these cells. Thus, combination of gelatin-GPTMS scaffolds and VEGF is preferable for brain regeneration.
Keywords: Brain, scaffold, tissue regeneration, vascular endothelial growth factor
Current Neurovascular Research
Title: Gelatin-Siloxane Hybrid Scaffolds with Vascular Endothelial Growth Factor Induces Brain Tissue Regeneration
Volume: 5 Issue: 2
Author(s): Hanzhe Zhang, Tatsushi Kamiya, Takeshi Hayashi, Kanji Tsuru, Kentaro Deguchi, Violeta Lukic, Atsushi Tsuchiya, Toru Yamashita, Satoshi Hayakawa, Yoshio Ikeda, Akiyoshi Osaka and Koji Abe
Affiliation:
Keywords: Brain, scaffold, tissue regeneration, vascular endothelial growth factor
Abstract: In the brain after infarction or trauma, the tissue becomes pannecrotic and forms a cavity. In such situation, a scaffold is necessary to produce new tissue. In this study, we implanted a new porous gelatin-siloxane hybrid derived from gelatin and 3-(glycidoxypropyl) trimethoxysilane (gelatin-GPTMS) scaffolds into a brain defect, and investigated whether it makes a new brain tissue. In addition, vascular endothelial growth factor (VEGF) was added on gelatin- GPTMS scaffolds and its effect on tissue regeneration was examined. At 30 days after the implantation, the marginal territory of the scaffolds became occupied by newly formed tissue. Immunohistochemical analysis revealed that the new tissue was constituted by endothelial, astroglial and microglial cells, some of which were labeled for bromodeoxyuridine (BrdU). Addition of VEGF promoted numbers of these cells. Thus, combination of gelatin-GPTMS scaffolds and VEGF is preferable for brain regeneration.
Export Options
About this article
Cite this article as:
Zhang Hanzhe, Kamiya Tatsushi, Hayashi Takeshi, Tsuru Kanji, Deguchi Kentaro, Lukic Violeta, Tsuchiya Atsushi, Yamashita Toru, Hayakawa Satoshi, Ikeda Yoshio, Osaka Akiyoshi and Abe Koji, Gelatin-Siloxane Hybrid Scaffolds with Vascular Endothelial Growth Factor Induces Brain Tissue Regeneration, Current Neurovascular Research 2008; 5 (2) . https://dx.doi.org/10.2174/156720208784310204
DOI https://dx.doi.org/10.2174/156720208784310204 |
Print ISSN 1567-2026 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5739 |
![](/images/wayfinder.jpg)
- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Natural Triterpenoids and their Derivatives with Pharmacological Activity Against Neurodegenerative Disorders
Mini-Reviews in Organic Chemistry Disrupted Functional Connectivity Related to Differential Degeneration of the Cingulum Bundle in Mild Cognitive Impairment Patients
Current Alzheimer Research The Oxygen Therapy
Current Medicinal Chemistry D1 and Functionally Selective Dopamine Agonists as Neuroprotective Agents in Parkinsons Disease
CNS & Neurological Disorders - Drug Targets Neonatal Fc Receptor and its Role in the Absorption, Distribution, Metabolism and Excretion of Immunoglobulin G-Based Biotherapeutics
Current Drug Metabolism Subject Index Volume 2
Current Pediatric Reviews Nongenomic Actions of Thyroid Hormones: Every why has a Wherefore
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) In Vitro and In Vivo Models of Multiple Sclerosis
CNS & Neurological Disorders - Drug Targets Riluzole, Neuroprotection and Amyotrophic Lateral Sclerosis
Current Medicinal Chemistry Human Urotensin II and Metabolic Syndrome
Vascular Disease Prevention (Discontinued) Astrocytic Signaling in Persistent Pain
Current Signal Transduction Therapy Autophagy as a Molecular Target of Flavonoids Underlying their Protective Effects in Human Disease
Current Medicinal Chemistry New Pharmacological Approaches in Infants with Hypoxic-Ischemic Encephalopathy
Current Pharmaceutical Design White Matter Injury Mechanisms
Current Molecular Medicine Potential Application of Induced Pluripotent Stem Cells in Cell Replacement Therapy for Parkinsons Disease
CNS & Neurological Disorders - Drug Targets Applications of Leukocyte- and Platelet-Rich Plasma (L-PRP) in Trauma Surgery
Current Pharmaceutical Biotechnology Cardiovascular Alterations After Spinal Cord Injury: An Overview
Current Medicinal Chemistry - Cardiovascular & Hematological Agents Cyclic AMP Enhancers and Aβ Oligomerization Blockers as Potential Therapeutic Agents in Alzheimers Disease
Current Alzheimer Research Optical Coherence Tomography Detection of Neurodegeneration in Multiple Sclerosis
CNS & Neurological Disorders - Drug Targets From Antidepressant Drugs to Beta-Mimetics: Preclinical Insights on Potential New Treatments for Neuropathic Pain
Recent Patents on CNS Drug Discovery (Discontinued)